LC pro active investors interview, page-9

JohnWayne... great minds think alike. that would all make sense, whether Gsk takes the entire Hervax package for themselves or a partnership / licensing deal going forward, either way it will push us into the big league , minimum 20_30c and like you say fully funds Pd1 and CF33 trials without another capital raise. All talk of cash in the bank should now at least factor in the A options, ~$6 million . Plus the B & C another ~$20 million over 2 years with sp above 5c.... Plus R&D rebates along the way.
The real question should be how much will a deal for HerVax add to the kitty, and how much will be paid back to shardholders via a distribution??? Suggest people do some homework on what these deals are really worth.